Latest COVID-19 vaccine may only be available to high-risk Americans as funds run out, Politico reports


  • A next-generation COVID-19 vaccine may only be available to high-risk Americans as funds run out, Politico reports.
  • An official close to this situation told Politico, “There is a great concern that we will get caught up in our dexterity.”
  • Even if new funding passes in Congress, it may not be enough to stop a future surge of the virus.

A next-generation COVID-19 vaccine may only be available to high-risk Americans as federal funds for the pandemic run out. According to a new report from Politico,.

According to Politico reporter Adam Cancryn, the White House is considering distributing future versions of the COVID-19 vaccine, such as a vaccine that could target the Omicron variant as cash supplies shrink.

As reported by CNBC, The United States currently does not have enough funds to purchase new vaccines, treatments, or test methods to combat potential future strains.

“We’re concerned that we might get caught up in dexterity,” a source told Politico.

A spokesperson for the Biden administration did not immediately respond to an insider’s request for comment.

The report says the White House could shift financing responsibilities to the private sector as early as 2023 and insurance companies could bear the costs. However, if the vaccine is not fully vaccinated for the uninsured, millions of people can be vulnerable.

Congress is debating $10 billion in additional funding for COVID-19, but Republicans are not backing the bill, putting new cash inputs at risk.

Politico reported that Republican lawmakers were skeptical of the need for more funding for the virus.

In fact, reports suggest Republicans are waiting on whether Biden will end COVID-era border restrictions that will allow more migrants from the southern border before Biden agrees to another funding package.

Nevertheless, if Congress passes the new funding package, it will be enough to keep some of the essential COVID-19 programs running, as at least half of Pfizer’s money that supplies 20 million doses of antiviral drugs owes Pfizer. Someone familiar with the situation told Politico.

Leave a Comment